The Journal of Immunology, Vol 143, Issue 6 1859-1867, Copyright © 1989 by American Association of Immunologists

ARTICLES

Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines

J Browning and A Ribolini
Department of Cell Biology and Immunology, Biogen Inc., Cambridge, MA 02142.

The relative ability of TNF and lymphotoxin (LT) to inhibit the growth of five human tumor cell lines was examined both in the presence and absence of IFN-gamma. Two adenocarcinoma lines, HT-29 and SK-CO-1, were 20- and 320-fold more sensitive to the inhibitory effects of TNF and LT in 3- to 4-day proliferation assays. In contrast, the breast carcinoma line BT-20 showed only a one- to twofold difference. The MCF-7 and ME- 180 cell lines exhibited intermediate behavior. These results parallel the reported disparate potencies of TNF and LT in their effects on endothelial cells, hematopoietic development and their abilities to sustain a mixed lymphocyte response. Radiolabeled TNF binding studies showed two classes of receptors (Kd 0.04 to 0.15 nM and 0.2 to 1.0 nM) on the highly sensitive SK-CO-1 line. HT-29 cells also appeared to possess some high affinity-binding sites, whereas the BT-20 line completely lacked the high affinity form. Thus the presence of high affinity-binding sites correlated with increased sensitivity to the antiproliferative effects of TNF. Cold TNF competed with the binding of radiolabeled human TNF three- to fivefold better than LT for binding to all three lines. These relatively small differences between the TNF and LT receptor-binding characteristics are insufficient to explain the dramatic disparity in their antiproliferative properties. Likewise, the absolute concentrations of the unlabeled cytokines necessary to block the binding of 125I-TNF were 10- to 150-fold higher than the levels necessary to elicit the biologic response. Thus, the receptor binding data conflict with the growth inhibitory effects. This discrepancy is discussed in terms of either separate receptors for TNF and LT or more complex phenomena such as receptor cooperativity possibly resulting from multivalent interactions with the trimeric form of TNF.

This article has been cited by other articles:

				J. Lama and C. F. Ware Human Immunodeficiency Virus Type 1 Nef Mediates Sustained Membrane Expression of Tumor Necrosis Factor and the Related Cytokine LIGHT on Activated T Cells J. Virol., October 15, 2000; 74(20): 9396 - 9402. [Abstract] [Full Text]

				W. R. Force, A. A. Glass, C. A. Benedict, T. C. Cheung, J. Lama, and C. F. Ware Discrete Signaling Regions in the Lymphotoxin-beta Receptor for Tumor Necrosis Factor Receptor-associated Factor Binding, Subcellular Localization, and Activation of Cell Death and NF-kappa B Pathways J. Biol. Chem., April 6, 2000; 275(15): 11121 - 11129. [Abstract] [Full Text] [PDF]

				E. Decoster, S. Cornelis, B. Vanhaesebroeck, and W. Fiers Autocrine Tumor Necrosis Factor (TNF) and Lymphotoxin (LT) alpha  Differentially Modulate Cellular Sensitivity to TNF/LT-alpha Cytotoxicity in L929 Cells J. Cell Biol., December 28, 1998; 143(7): 2057 - 2065. [Abstract] [Full Text] [PDF]

				M. Grell, H. Wajant, G. Zimmermann, and P. Scheurich The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor PNAS, January 20, 1998; 95(2): 570 - 575. [Abstract] [Full Text] [PDF]

				Y. Chicheportiche, P. R. Bourdon, H. Xu, Y.-M. Hsu, H. Scott, C. Hession, I. Garcia, and J. L. Browning TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis J. Biol. Chem., December 19, 1997; 272(51): 32401 - 32410. [Abstract] [Full Text] [PDF]

				W. R. Force, T. C. Cheung, and C. F. Ware Dominant Negative Mutants of TRAF3 Reveal an Important Role for the Coiled Coil Domains in Cell Death Signaling by the Lymphotoxin-beta Receptor J. Biol. Chem., December 5, 1997; 272(49): 30835 - 30840. [Abstract] [Full Text] [PDF]

				L. Williams-Abbott, B. N. Walter, T. C. Cheung, C. R. Goh, A. G. Porter, and C. F. Ware The Lymphotoxin-alpha (LTalpha ) Subunit Is Essential for the Assembly, but Not for the Receptor Specificity, of the Membrane-anchored LTalpha 1beta 2 Heterotrimeric Ligand J. Biol. Chem., August 1, 1997; 272(31): 19451 - 19456. [Abstract] [Full Text] [PDF]

				K. Sugie, T. Nakano, T. Tomura, K. Takakura, T. Mikayama, and K. Ishizaka High-affinity binding of bioactive glycosylation-inhibiting factor to antigen-primed T cells and natural killer cells PNAS, May 13, 1997; 94(10): 5278 - 5283. [Abstract] [Full Text] [PDF]

				T. L. VanArsdale, S. L. VanArsdale, W. R. Force, B. N. Walter, G. Mosialos, E. Kieff, J. C. Reed, and C. F. Ware Lymphotoxin-beta receptor signaling complex: Role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappa B PNAS, March 18, 1997; 94(6): 2460 - 2465. [Abstract] [Full Text] [PDF]

				A. E. Medvedev, T. Espevik, G. Ranges, and A. Sundan Distinct Roles of the Two Tumor Necrosis Factor (TNF) Receptors in Modulating TNF and Lymphotoxin alpha Effects J. Biol. Chem., April 19, 1996; 271(16): 9778 - 9784. [Abstract] [Full Text] [PDF]

				J. L. Browning, K. Miatkowski, D. A. Griffiths, P. R. Bourdon, C. Hession, C. M. Ambrose, and W. Meier Preparation and Characterization of Soluble Recombinant Heterotrimeric Complexes of Human Lymphotoxins alpha and beta J. Biol. Chem., April 12, 1996; 271(15): 8618 - 8626. [Abstract] [Full Text] [PDF]

				P. Crowe, T. VanArsdale, B. Walter, C. Ware, C Hession, B Ehrenfels, J. Browning, W. Din, R. Goodwin, and C. Smith A lymphotoxin-beta-specific receptor Science, April 29, 1994; 264(5159): 707 - 710. [Abstract] [PDF]